Visiongain Publishes Next-Generation Sequencing Market Report 2020-2030

29 July 2020

Visiongain has launched a new report Next Generation Sequencing Market Forecast 2020-2030: Forecasts by Next Generation Sequencing (NGS) Market by Product (Consumables, Platforms, and Services) Application (Biomarkers & Cancer, Diagnostics, Reproductive Health, Personalized Medicine, Agriculture & Animal Research, and Others), Technology (Sequencing by Synthesis, Ion Semiconductor Sequencing, Sequencing by Ligation, Pyrosequencing, Single Molecule Real Time Sequencing, and Other Technologies), and End-user (Academic & Clinical Research Centers, Pharmaceutical & Biotechnology Companies, Hospitals & Clinics, and Others) and by Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) Including Forecasts by Major Developed Countries and Developing Countries, Plus Profiles of Leading Companies.

Next-generation sequencing (NGS) is a high-throughput sequencing which allows for sequencing of millions and billions of DNA and RNA strands much more quickly and cheaply which has revolutionised the study of genomics and molecular biology. The all-in-one methodology obtainable by next generation sequencing curtails the time required to detect the cause of a condition, and compared to sequential molecular tests, thereby contributing to the improved health outcome. In the current scenario, liquid biopsies for early detection and monitoring of cancer, and diversification of the reproductive health market exhibits a large number of possibilities for the technology in the near future. NGS is used to execute various applications such as biomarker discovery, oncology studies, personalized medicine, agricultural & animal research, and others. NGS has streamlined nucleotide analysis and has broadly substituted conventional tools of genomics, especially microarray efficiently. Hence, these aforementioned factors have led to the increasing popularity of next generation sequencing driving the market growth.

Sequencing by synthesis (SBS), is one of the most prominent and greatly adopted next-generation sequencing (NGS) technologies used by researchers and scientist worldwide. In 2019, the SBS segment is estimated to be the dominant technology in the NGS market. The leading market position of this segment is mainly due to the development of new and advanced NGS platforms and the growing demand for Illumina’s systems, as it is the major provider of NGS platforms that use the SBS technology. Also, this technology offers a massive sequence throughput at modest costs, even in a single sequencing run.

The Visiongain report analyst commented “that with the reducing cost of sequencing, Next Generation Sequencing (NGS) is expected to witness diversification into a large number of clinical areas. Currently, next generation sequencing is accredited as the primary technology accountable for the burgeoning field of oncology, Mendelian diseases, and complex disease testing.”

Moreover, Next-generation sequencing has begun to transform prenatal diagnosis and prenatal Whole Exome Sequencing (WES) has become a reality. WES has enhanced genetic diagnosis by 16% to 45% in paediatric and adult populations. WES has also led to improvisation in detection of a genetic aetiology for prenatally diagnosed fatal structural abnormalities. Prenatal WES is usually performed as trio sequencing of fatal, maternal and paternal DNA to facilitate more rapid results. WGS could be helpful in understanding the alterations in the genetic sequence of the COVID-19 viral genomes collected from different patients thereby allowing researchers to build a viral ‘family tree’ and contribute to efforts to monitor disease spread within and between populations over time. The UK government has launched a new alliance to sequence the genomes of SARS-CoV-2, the virus responsible for the current COVID-19 pandemic. Funded by a £20 million investment, the COVID-19 Genomics UK Consortium (COG-UK) is comprised of the NHS, Public Health Agencies, the Wellcome Sanger Institute and several academic institutions. This could open several new opportunities to the manufacturers around the globe thereby driving the market growth during the forecast period. However, accuracy & standardization concerns and ethical & legal limitations associated with NGS restrain the market growth.

The report covers a detailed competitive outlook that includes market share and company profiles of key players operating in the global market. Key players profiled in the report include Illumina, Inc., Thermo Fisher Scientific, Inc., Pacific Biosciences of California, Inc., Beijing Genomics Institute, Qiagen N.V., 454 Life Sciences Corporation (Roche Holding AG), Agilent Technologies, Inc., Perkinelmer, Inc., Genomatix GmbH, and PierianDx.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Influenza Vaccines Market Report 2020-2030

For the companies operating in the global influenza vaccines market, there is an immense opportunity from emerging economies across the globe.

30 September 2020


Visiongain Publishes Next-Generation Pharmaceutical Temperature Management Solutions Market Report 2020-2030

Maintaining the quality and safety of the product in the supply chain has always been a high priority for pharmaceutical companies. New market dynamics including an evolving product line, more stringent regulations, geographically connected supply chains, rising risk, and extreme cost pressure have raised stakes significantly.

28 September 2020


Visiongain Publishes OTC Drugs & Dietary Supplements Market Report 2020-2030

The increasing rates of patent expiry lead to a counter-strategy of switching companies from Rx to OTC. In the US, according to the Consumer Healthcare Products Association, approximately 106 ingredients and dosage strengths have undergone a change from Rx to OTC to around 700 OTC products on the market.

23 September 2020


Visiongain Publishes Healthcare Cold Chain Logistics Market Report 2020-2030

. The growth of this market is majorly driven by increasing sales of temperature sensitive pharmaceutical products, longer life expectancy and rising geriatric population are some of the prominent factors.

16 September 2020